Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

291 - Efficacy of Tyrosine Kinase Inhibitors (TKIs) in Advanced Lung Adenosquamous Carcinoma


05 Apr 2019


Minjuan Hu


Annals of Oncology (2019) 30 (suppl_2): ii38-ii68. 10.1093/annonc/mdz063


M. Hu1, B. Zhang1, S. Wang2, Y. Shen1, J. Qian3, Y. Zhao4, B. Han5

Author affiliations

  • 1 Pulmonary Department, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 2 244 West Huaihai Road. Shanghai. China, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 3 Pulmonary Medicine, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 4 Respiratory Department, Shanghai Chest Hospital, 200030 - Shanghai/CN
  • 5 Shanghai Chest Hospital, 20030 - Shanghai/CN


Abstract 291


Adenosquamous carcinoma (ASC) is a rare type of lung cancers, with components of both squamous carcinoma and adenocarcinoma comprising to at least 10% of the tumor. EGFR-TKIs are playing an increasingly important role in the treatment of mutation-positive lung adenocarcinoma. However, the frequency and efficacy of multi-line EGFR-TKIs for ASC patients with sensitive EGFR mutations remain unclear.


From January 2010 to January 2018, patients pathologically diagnosed as lung ASC in Shanghai Chest Hospital were screened. The effectiveness of EGFR-TKIs in advanced ASC patients with EGFR mutation is retrospectively analyzed.


A total of 268 ASC patients were screened and 189 patients were tested for the presence of EGFR mutation. 101 positive patients were identified (53.0%, 95% CI, 46.3-60.6%), of which there are 43 19del, 44 21L858R mutations, 6 compound mutations or rare mutations, the rest lack of specific information. A higher frequency of EGFR mutation was found in younger, female patients who were non-smokers. We retrospectively collected consecutive survival data of 67 advanced ACS patients with EGFR-TKI therapy of different generations. Forty-six (46/52, 88.5%) patients had disease progression after first-generation EGFR-TKI treatment, with a median progression free survival (PFS) of 10.7 months (95% CI, 8.6-12.8 months) and a median duration of treatment (MDT) of 13.1 months (95% CI, 8.4-17.8 months). Median PFS for 15 eligible patients received third-generation TKI treatment was 10.2 months (95% CI, 8.3-12.1 months). Median overall survival (OS) for 14 eligible patients with multi-line EGFR-TKIs treatment was 42.1 months (95% CI, 15.7-68.5 months), compared to median OS of patients without third-generation treatment (25.1 months, 95% CI, 10.7-39.4) months.


Our data suggests the detection of EGFR mutations in patients with ASC, especially in young, female, non-smoking patients. The third-generation EGFR-TKI treatment could be a better choice to improve outcomes of advanced patients after progression of first-generation TKI.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Minjuan Hu.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings